Monday, May 13, 2024 4:13:22 PM
Why I think what you said is an incorrect conclusion of what Les has vomited.
First of all, as you say that is what you think of what Les said between the lines. Your interpretation
Second
If they asked for an extension RFI just in case on the first extension then that would mean that they received some pretty complicated and even critical questions. You don't ask for an extension on an RFI if the questions asked are simple and straightforward. If the questions are complicated and critical then that means that NWBO just may have to ADJUST the application. In that case its just no way NWBO will state in their 10Q that the application has not been amended to put investors in the wrong directions
Third. The MHRA is NOT fond of granting RFI extensions. So if NWBO requested an extension then NWBO has run into trouble answering the RFI which would be extremely bad news.
4th
EVERYTHING less said is utter sheit. Everything. I trust the 10Q x1000 more than what comes out of the piehole of that giant ass.
First of all, as you say that is what you think of what Les said between the lines. Your interpretation
Second
If they asked for an extension RFI just in case on the first extension then that would mean that they received some pretty complicated and even critical questions. You don't ask for an extension on an RFI if the questions asked are simple and straightforward. If the questions are complicated and critical then that means that NWBO just may have to ADJUST the application. In that case its just no way NWBO will state in their 10Q that the application has not been amended to put investors in the wrong directions
Third. The MHRA is NOT fond of granting RFI extensions. So if NWBO requested an extension then NWBO has run into trouble answering the RFI which would be extremely bad news.
4th
EVERYTHING less said is utter sheit. Everything. I trust the 10Q x1000 more than what comes out of the piehole of that giant ass.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
